The GLP-1 Results Timeline: What Week 1, Month 3, and the Plateau Actually Look Like
The most common question after starting a GLP-1 program isn't "will this work" — it's "when." Week one rarely looks like month three, and month three doesn't look like month twelve. This post walks through what published clinical trial data actually shows about that progression, stage by stage, using the same STEP-1 and SURMOUNT-1 trial data cited on our results page.
Two things worth stating plainly before the numbers: these figures are population averages from controlled clinical trials of the brand-name medications, not a personalized prediction for any one patient, and they're a different topic from what to expect physically in your first weeks — for dose titration and side effects specifically, see what to expect in your first month on GLP-1s. This post is about the shape of the results curve, not the side effect curve.
Weeks 1–4: Titration, Not Transformation
Your provider starts at a low dose and increases it gradually — that's not a formality, it's the mechanism that keeps side effects manageable. During this window, appetite changes and reduced "food noise" are commonly reported early, but weight change itself is typically modest. This is the phase where the medication is still reaching a therapeutic level in your system, not the phase where the bulk of the results happen.
If you're a week or two in and the scale hasn't moved much, that's consistent with what the trial data shows for this stage — not a sign that something is wrong.
Weeks 4–16 (Roughly Month 1 Through Month 4): The Active Response Window
Once dosing reaches a therapeutic level, this is the window where trial participants saw the steepest average rate of weight change. It's also, notably, when side effects — if they occur at all — are most common, since dose increases tend to happen during this stretch.
This is where the two medications' trial averages start to become meaningful reference points, not just headline numbers:
- STEP-1 (semaglutide, NEJM, 2021): participants averaged 14.9% body weight loss over 68 weeks.
- SURMOUNT-1 (tirzepatide, NEJM, 2022): participants averaged 22.5% body weight loss over 72 weeks.
Neither trial reports how much of that total happened by month three or four specifically — the published data is an endpoint average, not a week-by-week breakdown — so it would be inaccurate to hand you a specific "expected" number for this exact window. What the trial data does support is the general shape: this active-response period is where the rate of change is fastest for most people, which is different from claiming a fixed percentage by any particular date.
Months 4–12: Continued, Steadier Progress
Trial data shows average weight loss continuing through this period, but at a slower, steadier rate than the active-response window — and this is also where individual variation widens the longer someone stays on therapy. Two people starting at the same weight, on the same medication, can diverge meaningfully by month eight or nine based on adherence, dose, metabolism, and — something the trials themselves don't measure — whether they have structured coaching support alongside the medication.
This is also roughly where a maintenance plan needs to start taking shape, even though goal weight likely hasn't arrived yet. That timing isn't arbitrary: Bold You Wellness's own coaching curriculum begins maintenance planning around Month 4, specifically because waiting until goal weight to think about maintenance is, in practice, too late. More on why that timing matters below.
Month 15–18 (Roughly the Trial Endpoint) and Beyond: The Plateau and the Maintenance Turn
Both STEP-1 and SURMOUNT-1 observed weight stabilizing near their respective trial endpoints — 68 weeks and 72 weeks, or roughly month 15–18. A plateau at this stage isn't a failure of the medication; it's the trial data itself showing that this is where the curve is expected to flatten.
What happens after the plateau is the part that trial data alone can't answer, because it's not primarily a medication question anymore — it's a maintenance-planning question. This matters more than it might sound: Bold You Wellness's coaching program is built around a specific concern — weight regain after stopping a GLP-1 medication without a maintenance plan is a commonly reported pattern, which is why maintenance planning is treated as part of the program rather than an afterthought. That's not a knock against the medication — it's a description of what happens when a program stops planning the moment someone hits their number.
The alternative isn't complicated, just deliberate: maintenance planning that starts around Month 4 (not after the plateau), a curriculum that builds a real 12-month roadmap before goal weight arrives, and actual next-step options once you're there — a maintenance-dose microdosing protocol or a longevity add-on, rather than being handed a "congratulations" and nothing else.
The Honest Summary
- Weeks 1–4: titration, modest visible change, appetite effects often noticed first.
- Weeks 4–16: the fastest average rate of change in the trial data, and the window where dose-related side effects are most common.
- Months 4–12: continued but slower progress, with individual variation widening — and maintenance planning should already be starting.
- Month 15–18+: the trial data shows weight stabilizing — what happens next depends on the maintenance plan, not the prescription.
None of this is a promise about your specific timeline. STEP-1 and SURMOUNT-1 measured brand-name semaglutide and tirzepatide in controlled trial settings; Bold You Wellness prescribes compounded formulations of the same medication classes, and individual results vary significantly based on dose, adherence, coaching engagement, metabolism, and health history. If you want to see how these trial averages apply to your own starting numbers, the results page has a trial-average calculator built for exactly that — with the same caveat that it's a mathematical projection, not a medical prediction.
Clinical data cited above (STEP-1: 14.9% weight loss on semaglutide at 68 weeks; SURMOUNT-1: 22.5% weight loss on tirzepatide at 72 weeks) reflects outcomes in controlled clinical trial settings and is not representative of typical patient experience. Compounded medications referenced are prepared by FDA-registered 503A and 503B compounding pharmacies and are not FDA-approved finished drug products. Results vary. Not all patients will qualify.
Curious where you'd fall on this curve? Explore the Bold You Wellness weight loss program, or see the full trial-average breakdown on our results page.